Introduction
Cardiovascular physiology is profoundly regulated by multiple endocrine signals via nuclear and cell surface receptors, and age-related hormonal decline may increase the risk of cardiovascular disease (1). Current controversy regarding cardiovascular effects of hormone therapy (35, 38) emphasizes the need for research to enhance our understanding of steroid hormone actions on structural and functional changes in the blood vessel wall (7). Growing evidence suggests a role for estrogen Despite a large body of evidence on the biological actions of E 2 (33), there is a paucity of information on the biological actions of metabolites of E 2 such as the endogenous ER ligand E 3 which can be present at significant concentrations at the tissue level (5, 11, 19 ). E 3 is abundantly produced during late-stage pregnancy, and thus is present in conjugated equine estrogen preparations, which are known to relieve menopausal symptoms (43), has anti-atherosclerotic actions, improves endothelial and bone function (15), and ameliorates symptoms in autoimmune demyelinating disorders such as multiple sclerosis (21). Optimal homeostatic regulation of vascular tone and response to injury and inflammation may require a balance of multiple estrogenic metabolites in the vascular wall. For example, accruing evidence supports the concept of regulation of vascular proliferation by an array of steroid metabolites (4, 5) . However, there has been little or no investigation of effects of metabolite ER ligands on the regulation of vascular reactivity.
Our previous research has shown that both E 2 and progesterone (P) protect surgically menopausal Rhesus Macaque monkeys (RM) from in vivo CH and attenuate persistent Ca 2+ signals (27, 28) . In this study, experiments were designed to investigate the effects of endogenous ER ligand E 3 on regulation of in vivo CH.
Furthermore, we tested effects of E 3 and 3ßAdiol, (a dihydrotestosterone metabolite with ERβ agonist activity) (45) on Ca 2+ signals in coronary VMC and for comparison, examined the effects of the reported pharmacologically selective ERβ ligands DPN (40) and genistein (36) on Ca 2+ signals in coronary VMC. In addition, we examined the association of regulation of TPR expression with VMC reactivity using both immunocytochemistry and western blotting.
Methods

Transdermal Estriol (E3) Cream Application
Six adult female RM (Macaca mulatta), average age of 14.7 ± 1.8 years, average weight 6.4 ± 1.2 kg were used in these experiments. RM were ovariectomized (ovx) 1 month before beginning daily transdermal application of 1 ml of the 0.3% (gm/gm) E 3 skin cream for 28 days. RM were shaved in the mid-scapular area in preparation for application of 1 ml of the 0.3% (gm/gm) E 3 skin cream (3 mg of E 3 topically applied in each dose). The anticipated transdermal systemic absorption expected (7%) was about 0.2 mg. Trained personnel used a squeeze box cage for application of the drug through a window in the cage especially designed to allow optimal application with minimal animal discomfort. The cream covered an area of about 6 cm 2 on the shaved sub-scapular area on the backs of the trained RM without need for anesthetic or tranquilizer. Because this sub-scapular area is inaccessible for licking and minimally noticed by the RM, this site was used for subdermal or transdermal dosing for optimum steroid hormone delivery as reported previously (17).
Angiography data from 6 ovx historical control RM (untreated ovx) with average age 12.4±0.8 yr and average weight 6.1±0.5 kg performed utilizing the same laboratory, protocol, and investigators, were also included in the study analysis to compare the in vivo protective effects of E 3 against coronary hyperreactivity. These controls were considered appropriate since no specific effect of the vehicle in a placebo cream was anticipated based on previous demonstration of no treatment effect of placebo with exactly same formulation (minus the active pharmaceutical ingredient) applied following the same primate center protocol with the same special window cages (17).
Provocation of constriction to test for coronary hyperreactivity (CH)
Monkeys were subjected to the coronary artery combined vasoconstrictor stimulus in a catheterization laboratory protocol described previously (16, 17, 26, 28, 29, 31) . Briefly, the stepwise injection protocol tests the ability of slow (1 ml over 30 sec) intracoronary infusion of vasoactive endogenous substances, 100 µM serotonin (S) and 1 µM of the thromboxane analog, U46619 (U), to initiate the prolonged (>5 min), severe (to <33% of control diameter) vasoconstriction that defines CH producing ischemia, and if unrelieved, myocardial infarction. Acetylcholine-induced vasodilation of 5-8% was found in all E 3 treated RM, indicating normal endothelial dilator function. An observer blinded to the treatment groups measured coronary artery diameters (Φ) from serial angiograms to define the points of minimum Φ after each injection (16, 17, 26, 28, 29, 31). The corresponding anatomical point on the control image was the 100% reference Φ. Average minimum Φ of major epicardial coronary arteries were digitally analyzed to determine minimum Φ. A reduction in diameter to <33% of control for >5 minutes was classified as CH, whether or not focal vasospasm was observed (16, 17, 26, 28, 29, 31).
Fluorescence polarization ERβ coactivator assay
The Panvera fluorescence polarization ERβ co-activator assay (35) was performed according to the manufacturer's published protocol (PanVera Discovery Screening, Madison WI and Invitrogen, Carlsbad CA) to test ERβ agonist/antagonist activity of 3ßAdiol, DPN, genistein, E 3 , or R,R-THC studied individually using the ERβ coactivator assay along with reference agonists and antagonists. In the ERβ Coronary VMC culture protocols were performed as described previously (27-29). VMC Ca 2+ responses to 15 sec S+U pulse stimulation were determined as described previously (17, 27-29) after >72 hr in vitro exposure to ERß ligand (or placebo). When selective ERβ antagonist treatment (e.g. R,R-THC) was also performed, the antagonist was added to VMC culture plates 3 hr prior to subsequent treatment with the agonist 
Western blots
Western blots were performed as described previously (17 Unless otherwise specified, all other reagents were from Sigma-Aldrich Co, St. Louis MO.
Statistical Analysis
Results were compared by independent t-tests and by analysis of variance (ANOVA) using Origin software with p<0.05 taken as the level of statistical significance.
For angiographic data analysis, comparisons were made between minimal diameters in control and E 3 treated rhesus. For live cell fluorescence experiments, comparisons were made between Ca 2+ signals in ovx RM coronary control (untreated) VMC and VMC treated with the ERβ agonists E 3 , 3ßAdiol, DPN, or genistein, either alone or in the presence of the selective ERβ antagonist R,R-THC.
Results
E3 reduces in vivo CH
Angiography data showed that E 3 treatment effectively reduced S+U provoked persistent vasoconstriction when compared to controls (Fig 1A, E 3 treated ovx RM compared with untreated ovx RM). The hyperreactivity in one example ovx RM without E 3 treatment manifested in the form of a vasospasm (arrow) in Fig 1A, i.e., a severe segmental vasoconstriction to 10% of control Φ that persisted for >5 min. As a group, untreated ovx RM exhibited severe vasoconstrictions (<33% for 5-15 min, Φ = 25 ± 3.66 % of control, Fig 1B) meeting our criteria for coronary hyperreactivity (CH). In sharp contrast, E 3 treatment resulted in reduced and only transient vasoconstriction in every case. The minimum (constricted) epicardial coronary artery Φ exceeded 50% of the prestimulus size for the E 3 group (Φ = 63.87± 3.5 % of control, Fig 1B) . All 6 RM treated with E 3 showed no CH (by the <33% of control Φ for >5 min criterion) and completed the entire multiple challenge protocol without developing severe, persistent constriction.
ERβ agonist activity of 3ßAdiol, genistein, DPN, and E3
Fluorescence polarization analysis performed in a simultaneous series with ICI 187,780, tamoxifen, and 4-hydroxytamoxifen as positive controls demonstrated that according to changes in rotation of polarized light as affected by ligand to receptor binding, 3ßAdiol, E 3 , DPN, and genistein act as ERβ agonists, while R,R-THC is a ERβ antagonist (Fig 2A and 2B) . 
E 3 and 3ßAdiol attenuate late intracellular Ca 2+ signals
The remarkably potent effect of E 3 on reducing the duration and extent of provoked vasoconstriction in primate coronary angiographic studies, the documented affinity of 3ßAdiol for ERβ in rat prostate (45), and independent confirmation of ERβ agonist activity of E 3 and 3ßAdiol in the above ERβ coactivator fluorescence polarization assay prompted us to explore VMC effects of these endogenous metabolite ER ligands (in comparison with the more familiar pharmacological ERβ-selective probe genistein) on fluorescent intracellular Ca 2+ . The physiological range of circulating 3ßAdiol concentration is 100-800 pM in healthy women and men (12). We therefore tested effects of 3ßAdiol concentrations near these physiological concentrations.
Treatments with either 1 nM E 3 or 0.3 nM 3ßAdiol in vitro for 72 hr significantly reduced persistent (>30 min after the stimulus) Ca 2+ signals (Fig 3A) . VMC stimulation after 3ßAdiol (0.3 nM-3 nM) treatment resulted in significantly decreased late Ca 2+ signals compared to controls. However, 0.03 nM 3ßAdiol was ineffective in preventing late Ca 2+ signal increases (Fig 3B) , and thus defined the foot of the 3ßAdiol doseresponse curve. The low physiological range 72 hr treatment with 0.3 nM 3ßAdiol was as effective as using 1 nM 3ßAdiol in decreasing the late Ca 2+ increase, which suggests a sharp transition between lowest and middle concentration. The 3ßAdiol (0.3 nM) Ca 2+ suppressing effect was blocked by pretreatment with 30 uM of the specific ERß antagonist, R,R-THC (Fig 3C) .
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Statistical comparisons of the 30 min time point showed that the ERβ ligand genistein did not significantly reduce the late increase in Ca 2+ compared to untreated control VMC, while the recently discovered ERß agonists 3ßAdiol and DPN, like E 3 , significantly attenuated late Ca 2+ increases (Fig 3D) . There were no significant differences among E 3 , 3ßAdiol, and DPN in their abilities to significantly attenuate the late Ca 2+ signals. DPN 1 nM and genistein 10 nM concentrations used were chosen based on reported ERβ agonist EC 50 values (25).
In addition, 3ßAdiol not only significantly reduced the late Ca 2+ increase but also reduced early Ca 2+ signals (Fig 3C) . Because such reductions in intracellular Ca 2+ could hypothetically occur as direct (nongenomic) actions of 3ßAdiol on VMC, we also tested short-term incubations (5 to 60 min) with 3ßAdiol. There was no significant reduction in VMC Ca 2+ signals with any of the short-term (5 to 60 min) treatments with 3ßAdiol (data not shown).
R,R-THC blocked E 3 , 3ßAdiol, and DPN reduction of late Ca 2+ signals
Pretreatment with a selective ERβ antagonist, R,R-THC (30 µM) significantly blocked the effects of E 3 , 3ßAdiol, and DPN in reducing the persistent elevations in Ca 2+ (Fig 3D) . Incubation of VMC with R,R-THC (30 µM) alone for 1-6 hr had no significant effect on late Ca 2+ signals. R,R-THC concentration was chosen based on the molar ratios for selective ERβ block by R,R-THC in transactivation assays (24, 41). ERβ and TPR co-expression in primate coronary arteries and aorta (Fig 4A) . There was a dramatic attenuation of the TPR expression in aorta from E 3 treated RM compared to control RM (Fig 4B) . In addition, ERβ and TPR were co-expressed in ICC coronary VMC studies with a tendency for suppression of TPR in the E3 or 3bAdiol treated groups (Fig 4C) . In primary coronary VMC lysates, ERβ was detected as a 52 kDa protein band using mouse monoclonal ERβ antibody (Fig 5A) .
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E 3 and 3ßAdiol attenuated TPR expression in VMC which is blocked by R,R-THC
While ICC results only qualitatively implied decreased TPR expression by 3ßAdiol and E 3 (Fig 4C) , Western blotting demonstrated the quantitative reduction in TPR by either 3ßAdiol or E 3 (Fig 5B, C) . Studies of the other ERß ligands, with or without R,R-THC, on TPR expression showed that in vitro treatment with either DPN or genistein also significantly decreased TPR. There were no significant differences among the effects of ERβ agonists in attenuating TPR. Although R,R-THC alone did not significantly change TPR expression (data not shown), R,R-THC pre-treatment significantly blocked the reduction in TPR by either E 3 , or 3ßAdiol (Fig 5B, C) . Likewise R,R-THC significantly blocked the reduction in TPR by genistein or DPN (Fig 5B, C) .
Discussion
This study is the first demonstration of a coronary protective effect of low dose transdermal E 3 in a surgically menopausal primate model, as evidenced by the reduction of in vivo CH. Reduction of CH by E 3 treatment was in fact equivalent to reduction of CH in previous primate studies that used 2-4 week treatments with E 2 subdermal implants with plasma E 2 levels of 60 pg/ml (26, 27, 31). Although GC-MS demonstrated that serum E metabolites in the E 3 treated rhesus remained at ovx levels (data not shown), and in spite of a short half-life (due to single pass through the liver) with rapid glucuronide or sulfate conjugation and subsequent rapid renal excretion, application of transdermal low dose E 3 for four weeks significantly reduced CH.
Whereas the literature is replete with evidence (both animal and human data) supporting beneficial cardiovascular effects of E 2 , there are few studies examining E 3 actions on cardiovascular pathophysiology. In a spontaneously hypertensive strokeprone rat model of moderate renal dysfunction, E 3 treatment significantly reduced cardiac lesions (10). In humans, E 3 augments the beneficial effect of pravastatin in retarding the progression of atherosclerosis in postmenopausal women (48) and improves endothelial function (14). Despite these recent data on favorable cardiovascular effects of E 3 , the exact role of E 3 in cardiovascular physiology remains to be determined. Formation of E 3 from E 2 may allow continued stimulation of ER at the vascular tissue level thereby sustaining the biological effects of E 2 . Furthermore, being less potent than E 2 , E 3 may allow fine tuning via stimulation of ER of responses at the tissue and cellular level.
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In the ERβ co-activator assay, the EC 50 values for E 3 , 3ßAdiol, and DPN were equivalent, suggesting similar ERβ agonist activity, and there were no significant differences among E 3 , 3ßAdiol, and DPN in reducing the late intracellular Ca 2+ signals. predominates in the endothelium, but ERß predominates in vascular muscle. Recent data suggest that E 2 contributes to the vascular healing process and that prevention of re-stenosis occurs by promoting re-endothelialization via ERα activation (9). There may be a concomitant decrease in vascular muscle cell migration and proliferation via ERβ actions that allows for repair without occlusion (9). ERβ may also mediate gender differences in ischemia reperfusion injury, as ERβ KO female mice display significantly less functional recovery (and more necrosis) than wild type female (or male) control mice, and thus ERβ may have a greater cardioprotective role in females (8).
COX-2 (Cyclooxygenase-2 enzyme) is an enzyme that is the dominant source of protaglandins that mediate pain and inflammation, but also biosynthesis of the cardiovascular protective substance, prostacyclin, which is a short lived autocoid that is 
